Rearrangements of the ROS1 gene occur in 1–2% of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

Immunohistochemistry is a widely available technique that is less challenging and can
provide clinically meaningful results quickly and cost-efficiently in comparison with other …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …

Purpose ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer
(NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1 …

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1
rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains …

The surge of fast-spreading SARS-CoV-2 mutated variants highlights the need for fast,
broad-spectrum strategies to counteract viral infections. In this work, we report a physical …

Introduction PD-L1 expression is a predictive biomarker for response to anti-programmed
cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors …

The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung
cancer (NSCLC) depends on the accurate determination of the genomic status of the …

Abstract Objective The World Health Organization Classification of Lung Tumors considers
“Spread Through Air Spaces (STAS)” as a form of invasion in lung adenocarcinoma …